Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis - Gabay, C; McInnes, I B; Kavanaugh, A (Ann Rheum Dis, 2016)
et al.